PSA immunoreactivity detected in LNCaP cell medium, breast tumor cytosol, and female serum.
We made an effort to identify a reliable source for obtaining large quantities of both free (PSA) and PSA-ACT complex for the preparation of the calibrator for the PSA assay. Using size exclusion chromatography, we found both free PSA and PSA-ACT complex in the conditioned cell medium of the LNCaP cell line, which was derived from a human metastatic adenocarcinoma of the prostate. An assay specific for PSA-ACT reacted only with the PSA-ACT complex from cells grown in serum-free medium, and not with the complex from the cell medium grown in 10% calf serum. We also found both free PSA and PSA-ACT complex in 15% of cytosols prepared from breast tumor tissues; the cytosol PSA concentrations ranged from 0.1 to 110 ng/ml. No correlation was found between cytosol PSA and concentrations of estrogen receptor, progestin receptor, epidermal growth factor receptor, cathepsin D, or the ectodomain of c-erbB-2 protein. Based on chromatographic characterizations and the slope of their dose-response curves, it appears that both free PSA and PSA-ACT complex found in the cytosols are similar to PSA complex from the cell medium and the serum of prostate cancer patients. Ectopic PSA was also detected in pooled sera from patients with breast, ovarian, pancreatic, and colon carcinoma. The PSA concentrations in these serum pools increased with the level of their dominant tumor marker. In any event, the LNCaP cell medium appears to be a reliable source for obtaining both free and ACT-complexed PSA of human tumor origin for the preparation of PSA assay calibrators.
Wu
J T
JT
Department of Pathology, University of Utah School of Medicine, Salt Lake City, USA.
Zhang
P
P
Astill
M E
ME
Wilson
L W
LW
Lyons
B W
BW
Wu
L L
LL
Stephenson
R
R
D001943:Breast Neoplasms / Q000737:chemistry*; D002850:Chromatography, Gel; D003110:Colonic Neoplasms / Q000737:chemistry; D017077:Culture Media, Conditioned / Q000737:chemistry; D003600:Cytosol / Q000737:chemistry*; D005260:Female; D006801:Humans; D008297:Male; D010051:Ovarian Neoplasms / Q000737:chemistry; D010190:Pancreatic Neoplasms / Q000737:chemistry; D017430:Prostate-Specific Antigen / Q000032:analysis* / Q000097:blood / Q000276:immunology; D011471:Prostatic Neoplasms / Q000737:chemistry*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012307:Risk Factors; D014407:Tumor Cells, Cultured; D000514:alpha 1-Antichymotrypsin / Q000032:analysis* / Q000097:blood
D017077:Culture Media, Conditioned; D017430:Prostate-Specific Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000514:alpha 1-Antichymotrypsin